Global Cancer Immunotherapy Market Research Report: By Type of Therapy (Monoclonal Antibodies, Adoptive Cell Transfer and others), By Application (Lung Cancer, Childhood Cancer and other), By End User (Hospitals, Clinics & others) - Forecast till 2023

Market Scenario

Global cancer immunotherapy market has been growing at a impressive rate in recent years and will maintain the same in coming future. Approximately 100 different types of cancer have been identified. Cancer is condition of uncontrolled cell growth. Cancer Immunotherapy, on the other hand, helps the immune system to target cancerous tumor cells, which is in fact the natural tendency of the body but tends to weaken with the advent of disease infections. According to W.H.O. cancer is the leading cause of the total number of deaths globally in 2015, and was responsible for 8.8 million deaths in 2015. Statistics suggest that nearly 1 in 6 patients die due to cancer. Due to deteriorating lifestyle, smoking, and alcoholism are responsible for increasing the incidence of cancer. Increasing cancer population is the major reason for increasing the global immunotherapy market. Many therapies are available in the market but the advantage of immunotherapy is its high effectiveness and less side effects as compared to other therapies. This therapy is effective for patients suffering from melanoma cancer when chemotherapy and other radiation therapies do not work.

The respective statistics of deaths occurring due to lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer were recorded to be found as 16,90,000, 788,000, 774,000, 754,000, and 571,000 respectively, in 2015

Most common cancers are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer, which have been recorded to cause 1.69 million, 788,000, 774 thousands, 754 thousands, and 571 thousands deaths respectively in year 2015.

According to CDC, more than 1.5 million people are diagnosed with cancer every year in the U.S., and more than 5 lakhs people are not able to survive. Reports show that 50 % of the total deaths could be prevented through making a healthy choice. Smoking is the leading cause of lung cancer, which is responsible for 90 % of the total deaths in men and 80% in women.

Global immunotherapy market was USD 36.8 billion in 2016 which is expected to grow at a healthy CAGR of 14.8% and reach till USD 101.6 billion by 2023.

Research Methodology
Intended Audience

- Government and private research companies
- Research and Development (R&D) Companies
- Drug Manufacturers and Suppliers
- Hospitals and Laboratories
- Medical Research Laboratories

Segmentations

The global cancer immunotherapy market is segmented on the basis of therapy types, by application, by end user.

On the basis of type, it is segmented into monoclonal antibodies, adoptive cell transfer, cytokines, treatment vaccines, bacillus calmette-guérin, and others. Monoclonal antibodies segment is further segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies. Cytokines are further segmented into Interferon, Interleukins.

On the basis of application, it is segmented into liver cancer, childhood cancer, colorectal cancer, stomach cancer, lung cancer and others.

On the basis of end user, it is segmented into hospitals, clinics, and others.

Figure: Global Cancer Immunotherapy Market, by type of therapy Market Share, 2016 (%)
Regional Analysis

Global cancer immunotherapy market is segmented into four main geographical region, they are North America, Europe, Asia Pacific and The Middle East and Africa.

Over the last few years, North America and Europe are the major contributors in the global cancer immunotherapy market. Due to their reputation as a suitable place for research and development. The market for cancer immunotherapy has a huge demand in both region and is expected to grow in coming future.

Asia Pacific is however the fastest growing cancer immunotherapy market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover increasing demand for new treatment methods in countries like India and South Korea are likely to emerge as the fastest growing market across the globe.

The Middle East and Africa holding the least growth in comparison to other region, although, increasing occurrence of cancer owing to smoking, change in lifestyle, and excessive alcohol intake are driving the cancer immunotherapy market in this region.

Key Players

Some of key the players in the market are F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, GlaxoSmithKline Plc., Amgen Inc., Bristol-Myers Squibb, ELI Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc.
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Cancer Immunotherapy Market, By Therapy Type
6.1 Introduction
6.2 Monoclonal Antibodies
6.2.1 Market Estimates & Forecast, 2017-2023
6.3 Adoptive cell transfer
6.3.1 Market Estimates & Forecast, 2017-2023
6.4 Cytokines
6.4.1 Interferon (INFs)
6.4.2 Interleukins (ILs)
6.4.3 Market Estimates & Forecast, 2017-2023
6.5 Treatment Vaccines
6.5.1 Market Estimates & Forecast, 2017-2023
6.6 Bacillus Calmette-Guérin
6.6.1 Market Estimates & Forecast, 2017-2023
6.7 Others

7. Global Cancer Immunotherapy Market, By Application
7.1 Introduction
7.2 Liver cancer
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Childhood cancer
7.3.1 Market Estimates & Forecast, 2017-2023
7.4 Colorectal cancer
7.4.1 Market Estimates & Forecast, 2017-2023
7.5 Stomach cancer
7.5.1 Market Estimates & Forecast, 2017-2023
7.6 Lung cancer
7.6.1 Market Estimates & Forecast, 2017-2023
7.7 Others

8. Global Cancer Immunotherapy Market, by End User
8.1 Introduction
8.2 Hospitals
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Clinics
8.3.1 Market Estimates & Forecast, 2017-2023
8.4 Others

9. Global Cancer Immunotherapy Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

11 Company Profiles
11.1 F. Hoffmann-La Roche AG
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Merck & Co., Inc.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Novartis International AG
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 GlaxoSmithKline Plc
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Amgen Inc.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financials Overview
11.5.4 Key Developments
11.5.6 Bristol-Myers Squibb
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Eli Lilly and Company
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8Celgene Corporation
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Seattle Genetics, Inc.
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Spectrum Pharmaceuticals, Inc.
11.10.1 Overview
11.10.2 Product Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10 Others

12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO's View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical Industry

13 Appendix
LIST OF TABLES
Table 1 Cancer Immunotherapy Industry Synopsis, 2017-2023
Table 2 Global Cancer Immunotherapy Market Estimates and Forecast, 2017-2023, (USD Million)
Table 3 Global Cancer Immunotherapy Market by Region, 2017-2023, (USD Million)
Table 4 Global Cancer Immunotherapy Market by Therapy Therapy Types, 2017-2023, (USD Million)
Table 5 Global Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)
Table 6 Global Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)
Table 7 North America Cancer Immunotherapy Market by Therapy Therapy Types, 2017-2023, (USD Million)
Table 8 North America Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)
Table 9 North America Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)
Table 10 U.S. Cancer Immunotherapy Market by Therapy Therapy Types, 2017-2023, (USD Million)
Table 10 U.S. Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)
Table 12 U.S. Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)
Table 13 Canada Cancer Immunotherapy Market by Therapy Therapy Types, 2017-2023, (USD Million)
Table 14 Canada Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)
Table 15 Canada Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)
Table 16 South America Cancer Immunotherapy Market by Therapy Therapy Types, 2017-2023, (USD Million)